10-year Comparative Effectiveness and Harms of Treatments for Prostate Cancer
10-year Comparative Effectiveness and Harms of Treatments for Prostate Cancer
批准号:
10602465
负责人:
Daniel A Barocas
金额:
$55.43万
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-04-01 至 2024-09-30
关键词:
3-DimensionalAgeAnxietyCharacteristicsClinicalCohort StudiesCollaborationsComparative StudyConformal RadiotherapyData CollectionData ReportingDiagnosisDiseaseDisease ManagementEffectivenessElderlyEnrollmentErectile dysfunctionEthnic OriginEventFamily memberFatigueFinancial HardshipFractureIncontinenceIndividualInterviewIntestinesKnowledgeLiteratureLongitudinal StudiesMalignant NeoplasmsMalignant neoplasm of prostateMedicalMedical RecordsMental DepressionMethodsNewly DiagnosedOperative Surgical ProceduresOutcomePainParticipantPatient Outcomes AssessmentsPatient PreferencesPatientsPhysical FunctionPopulation StudyProcessProctitisProstate Cancer therapyProviderPublicationsQualitative ResearchQuality of lifeRaceRadiationRadiation therapyRadical ProstatectomyRecurrenceReportingResearch PersonnelRiskRisk AdjustmentSalvage TherapySeverity of illnessSex FunctioningStructureSurveysTelephone InterviewsTimeToxic effectUncertaintyUrinary Incontinencecohortcomorbiditycomparativecomparative effectivenesscomparative effectiveness analysisdisorder riskemotional functioningexperiencefinancial toxicityfunctional outcomeshigh riskhormone therapyimprovedinstrumentmenminority patientpatient subsetspopulation basedprostate cancer riskradiation cystitisrandomized trialrandomized, clinical trialsshared decision makingside effectsurgery outcometreatment effecttumor progressionurinary
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary
The available literature regarding comparative effectiveness and comparative harms of management options
for localized prostate cancer is inadequate to power a shared decision-making process between patients and
providers. The few randomized trials that exist are flawed in important ways, leaving enormous uncertainty about
how best to manage newly diagnosed prostate cancer, and possible trade-offs between side-effects and efficacy
of surgery, radiation and active surveillance. A well-executed long-term, population-based study that assesses
real-world outcomes in a diverse cohort would add considerably to the literature and could overcome some of
the limitations of earlier randomized clinical trials. The Comparative Effectiveness Analysis of Surgery and
Radiation (CEASAR) cohort is a population-based cohort study of approximately 3000 men (over 25% non-white)
with localized prostate cancer, accrued in 2011-12. Longitudinal patient-reported data have been collected out
to 5 years, and a medical chart review was performed 12 months after diagnosis. This cohort provides an
invaluable opportunity to study comparative long-term oncologic and quality of life outcomes. In addition, its
diversity and breadth make in an ideal cohort in which to study the influence of patient characteristics, such as
baseline disease risk stratum, race, age and comorbidity, on these downstream outcomes. The Specific Aims
are to:
1. Compare the clinical outcomes of surgery, radiation and active surveillance (cancer outcomes and
complications).
2. Compare patient-reported outcomes of these management options with respect to disease-specific and
general quality of life outcomes, financial toxicity, and qualitative outcomes
3. Explore the influence of baseline patient characteristics on the oncologic and quality of life outcomes.
In order to accomplish these Aims, we will perform a patient survey and medical chart review 10 years after
diagnosis, and we will perform structured qualitative research interviews with a sub-set of patients. The proposed
study draws on the experience of the CEASAR investigators who have collaborated successfully since 2009 on
the planning and execution of several rounds of data collection, analysis and publication. The results of this study
will be utilized to inform the shared decision-making process, in order to improve concordance between treatment
decisions and patient preferences and priorities.
期刊论文(4)
专著(0)
科研奖励(0)
会议论文
The lived experience of prostate cancer: 10-year survivor perspectives following contemporary treatment of localized prostate cancer.
前列腺癌的生活经历:局部前列腺癌当代治疗后 10 年幸存者的观点。
DOI:
10.1007/s11764-023-01381-6
发表时间:
2023
期刊:
Journal of cancer survivorship : research and practice
影响因子:
--
作者:
[AlHusseinAlAwamlh,Bashir, Wallis,ChristopherJD, Diehl,Carolyn, Barocas,DanielA, Beskow,LauraM]
通讯作者:
Beskow,LauraM
Functional Outcomes After Localized Prostate Cancer Treatment.
局部前列腺癌治疗后的功能结果。
DOI:
10.1001/jama.2023.26491
发表时间:
2024
期刊:
JAMA
影响因子:
--
作者:
[AlHusseinAlAwamlh,Bashir, Wallis,ChristopherJD, Penson,DavidF, Huang,Li-Ching, Zhao,Zhiguo, Conwill,Ralph, Talwar,Ruchika, Morgans,AliciaK, Goodman,Michael, Hamilton,AnnS, Wu,Xiao-Cheng, Paddock,LisaE, Stroup,Antoinette, O'Neil,Broc]
通讯作者:
O'Neil,Broc
DOI:
10.1093/jncics/pkac071
发表时间:
2022-11-01
期刊:
JNCI cancer spectrum
影响因子:
4.4
作者:
[]
通讯作者:
10-year Comparative Effectiveness and Harms of Treatments for Prostate Cancer
-
批准号:9904587
-
项目类别:
-
资助金额:$63.59万
-
财政年份:2019
-
负责人:Daniel A Barocas
-
依托单位:
10-year Comparative Effectiveness and Harms of Treatments for Prostate Cancer
-
批准号:10372985
-
项目类别:
-
资助金额:$60.64万
-
财政年份:2019
-
负责人:Daniel A Barocas
-
依托单位:
Trends in Surveillance for Localized Prostate Cancer and Barriers to its Use
-
批准号:8445675
-
项目类别:
-
资助金额:$7.8万
-
财政年份:2013
-
负责人:Daniel A Barocas
-
依托单位:
Trends in Surveillance for Localized Prostate Cancer and Barriers to its Use
-
批准号:8600663
-
项目类别:
-
资助金额:$7.57万
-
财政年份:2013
-
负责人:Daniel A Barocas
-
依托单位:
The Quality of Care in Evaluating Patients Suspected of Having Bladder Cancer
-
批准号:8446036
-
项目类别:
-
资助金额:$7.8万
-
财政年份:2013
-
负责人:Daniel A Barocas
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: